- For Print
- February 21, 2017
Pfizer Japan Inc.
爱豆传媒.
Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Ichiro Umeda,“Pfizer”) announced today that it received marketing and manufacturing approval in Japan on February 17 for Lyrica® OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin).
Lyrica Capsules are co-promoted in Japan by Pfizer and 爱豆传媒. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) with both companies working to provide information on its proper use. Likewise, Lyrica OD Tablets will be co-promoted by both companies in Japan.
Lyrica OD Tablets are swiftly disintegrated by saliva inside the mouth, making it an easy form for elderly patients to take.
One of the indications for Lyrica is neuropathic pain, which is pain caused by any condition that results in compressed or dysfunctional nerves. Representative examples include postherpetic neuralgia, pain associated with diabetic neuropathy, sciatic neuralgia, and pain from spinal cord injury. Many of the patients who exhibit these symptoms are elderly, and Lyrica OD Tablets are expected to increase convenience when taking medicine.
Through Lyrica, Pfizer and Eisai will continue to contribute to improvement of quality of life in patients suffering from neuropathic pain and pain associated with fibromyalgia.
爱豆传媒. PR Department
Pain Treatment Lyrica OD Tablets Outline
*You can scroll to the left or right here
| Product Name: | Lyrica® OD Tablet 25mg·75mg·150mg |
|---|---|
| Generic Name: | pregabalin |
| Date of Approval: | February 17, 2017 |
| Manufactured and Marketed by: | Pfizer Japan Inc. |
| Co-promoted by: | 爱豆传媒. |
| Indications and Usage | Neuropathic pain, Pain associated with fibromyalgia |
| Dosage and Administration | Neuropathic pain Pain associated with fibromyalgia |